REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao
29 November 2017
New Cell Therapies for Central Nervous System Diseases Using IPSC-Derived Products YOKOHAMA, JAPAN & SALT LAKE CITY, UTAH – November 29th, 2017 – REPROCELL, Inc. announced a collaborative research agreement with Q Therapeutics, Inc. that co...
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
22 November 2016
REPROCELL announces an entrustment contract with Healios K.K. (headquarters: Minato Ward, Tokyo; president and CEO: Tadanao Kagimoto; hereafter, Healios) for sample testing support of human clinical trials conducted by Healios, as well as t...
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
16 November 2016
Today, REPROCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system ...
A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality
16 November 2015
Company: REPROCELL, Inc. (JASDAQ Company code: 4978) Representative: Chikafumi Yokoyama, PhD Contact: info-us@reprocell.com “ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the ...
Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells
04 November 2015
Company: REPROCELL,Inc. (JASDAQ Company code: 4978) Representative: Chikafumi Yokoyama, PhD Contact: info-us@reprocell.com We would like to inform you that a patent application concerning an amplification method of hematopoietic stem cells ...
The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal
14 October 2015
Company: REPROCELL,Inc. (JASDAQ Company code: 4978) Representative: Chikafumi Yokoyama, PhD Contact: info_en@reprocell.com Group affiliate Stemgent Inc. (US) is pleased to announce the publication of a paper on state-of-the-art iPS cell pro...
REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells
08 September 2015
Company: REPROCELL, Inc. (JASDAQ Company code: 4978) Representative: Chikafumi Yokoyama, PhD Contact: info-us@reprocell.com We are pleased to announce that our company has entered into an exclusive licensing agreement with Keio University r...
Announcement: New High Performance Cryopreservation Solution – ReproCryo DMSO Free
26 August 2015
Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University: New high-performance cryopreservation solution for human ES/iPS cells used in regenerative medicine Notice of the commencement of sales of “ReproCryo D...
Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes
14 August 2015
Announcement: REPROCELL’s project, “Prototype Development of a Large-Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells”, has been chosen to receive a Subsidy for Collaborative Projects to Advance th...
Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”
29 July 2015
Company: REPROCELL,Inc. (JASDAQ Company code: 4978) Representative: Chikafumi Yokoyama, PhD Contact: info-us@reprocell.com We are pleased to announce that on August 10th our company began sales of “ReproNeuro AD-patient,” diseased neurons m...